LogicBio Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- LogicBio Therapeutics's estimated annual revenue is currently $4M per year.
- LogicBio Therapeutics received $50.0M in venture funding in June 2017.
- LogicBio Therapeutics's estimated revenue per employee is $201,500
- LogicBio Therapeutics's total funding is $69M.
Employee Data
- LogicBio Therapeutics has 20 Employees.
- LogicBio Therapeutics grew their employee count by -9% last year.
LogicBio Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is LogicBio Therapeutics?
We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types.
keywords:N/A
$69M
Total Funding
20
Number of Employees
$4M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
LogicBio Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Principal Scientist | Reveal Email/Phone |
2 | Research Associate | Reveal Email/Phone |
3 | Principal Scientist/Team Lead | Reveal Email/Phone |
4 | Principal Research Associate | Reveal Email/Phone |
5 | Scientist | Reveal Email/Phone |
6 | Attaché | Reveal Email/Phone |
7 | General Counsel and Secretary | Reveal Email/Phone |
8 | VP & Head Technology Development | Reveal Email/Phone |
9 | Senior Research Associate | Reveal Email/Phone |
10 | Vivarium and Lab Operations Manager | Reveal Email/Phone |
LogicBio Therapeutics News
LogicBio Therapeutics (NASDAQ:LOGC) shares are surging over 34% in pre-market trading this morning. NewAge (NASDAQ:NBEV) stock is climbing...
This is a summary of recent recommendations for Voyager Therapeutics and LogicBio Therapeutics, as provided by MarketBeat.com. Sell Ratings...
LogicBio Therapeutics, Inc engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide,...
LEXINGTON, Mass. - LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, announced several preclinical data presentations, including an oral pre ...
Arix Bioscience PLC (ARIX) LogicBio announces clinical and corporate updates 27-Apr-2021 / 14:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. =------------------------------------------------- ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 20 | N/A | N/A |
#2 | $1.5M | 20 | -47% | N/A |
#3 | $3.1M | 20 | 11% | N/A |
#4 | $2M | 20 | -13% | N/A |
#5 | $2.9M | 20 | 5% | N/A |
LogicBio Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-06-29 | $50.0M | Undisclosed | Multiple | Article |